Biotherapeutics, Inc., a Blacksburg, VA-based company advancing therapeutics to treat inflammation and diabetes, received a funding from CIT GAP Funds.
The amount of the funding wqas not disclosed.
The company intends to use the funds to perform additional safety and efficacy studies for its lead compounds and advance them along the regulatory pipeline towards investigational new drug (IND) approval.
Established in 2008 and led by Josep Bassaganya-Riera, PhD, President and CEO, BioTherapeutics is a pre-clinical stage company that has developed a platform for developing effective small-molecule drugs to treat inflammation associated with autoimmune related disorders and diabetes by targeting novel therapeutic targets.
FinSMEs
23/09/2014